203 related articles for article (PubMed ID: 8408793)
1. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity.
Kecskés A; Heger-Mahn D; Kuhlmann RK; Lange L
J Am Acad Dermatol; 1993 Oct; 29(4):576-80. PubMed ID: 8408793
[TBL] [Abstract][Full Text] [Related]
2. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate.
Mirshahpanah P; Döcke WD; Merbold U; Asadullah K; Röse L; Schäcke H; Zollner TM
Exp Dermatol; 2007 Sep; 16(9):753-61. PubMed ID: 17697148
[TBL] [Abstract][Full Text] [Related]
3. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
5. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema.
Alomar A; Puig L; Gallardo CM; Valenzuela N
Contact Dermatitis; 2003 Oct; 49(4):185-8. PubMed ID: 14996065
[TBL] [Abstract][Full Text] [Related]
6. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis.
Vernon HJ; Lane AT; Weston W
J Am Acad Dermatol; 1991 Apr; 24(4):603-7. PubMed ID: 2033138
[TBL] [Abstract][Full Text] [Related]
8. Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential.
Katz HI; Prawer SE; Watson MJ; Scull TA; Peets EA
Int J Dermatol; 1989 Jun; 28(5):342-4. PubMed ID: 2753592
[No Abstract] [Full Text] [Related]
9. Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis.
Medansky RS; Cuffie CA; Tanner DJ
Clin Ther; 1997; 19(4):701-9. PubMed ID: 9377614
[TBL] [Abstract][Full Text] [Related]
10. Multiple corticosteroid allergies.
Chow ET
Australas J Dermatol; 2001 Feb; 42(1):62-3. PubMed ID: 11233727
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic index makes easier the choice of admissible substances. No fear concerning cortisone].
MMW Fortschr Med; 2003 Jul; 145(27-28):64. PubMed ID: 14587199
[No Abstract] [Full Text] [Related]
13. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.
Prakash A; Benfield P
Drugs; 1998 Jan; 55(1):145-63. PubMed ID: 9463794
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses.
Kelly JW; Cains GD; Rallings M; Gilmore SJ
Australas J Dermatol; 1991; 32(2):85-91. PubMed ID: 1781761
[TBL] [Abstract][Full Text] [Related]
15. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses.
Viglioglia P; Jones ML; Peets EA
J Int Med Res; 1990; 18(6):460-7. PubMed ID: 2292327
[TBL] [Abstract][Full Text] [Related]
16. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
Koo JY; Martin D
Int J Dermatol; 2001 Mar; 40(3):210-2. PubMed ID: 11422529
[No Abstract] [Full Text] [Related]
17. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers.
Kecskés A; Jahn P; Wendt H; Kleine-Kuhlmann R; Lange L
Arzneimittelforschung; 1993 Feb; 43(2):144-7. PubMed ID: 8457237
[TBL] [Abstract][Full Text] [Related]
18. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA
Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of activity of different topical corticosteroid creams and ointments using a vasoconstriction assay: superiority of hydrocortisone butyrate over hydrocortisone].
Korting HC; Maslen K; Gross G; Willers C
J Dtsch Dermatol Ges; 2005 May; 3(5):348-53. PubMed ID: 16372801
[TBL] [Abstract][Full Text] [Related]
20. Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment.
Nissen JB; Avrach WW; Hansen ES; Stengaard-Pedersen K; Kragballe K
Dermatology; 1999; 198(1):11-7. PubMed ID: 10026395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
